Treatment of langerhans cell histiocytosis with pamidronate

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 1, 2001, Pages 54-56

  Peter Farran, R ^a   Zaretski, Eldon ^a   Maarten Egeler, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Analgesics; Biphosphonates; Langerhans cell histiocytosis; Osteolytic lesions; Pain

Indexed keywords

ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BONE PAIN; CASE REPORT; HISTIOCYTOSIS; HUMAN; LANGERHANS CELL; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; DIPHOSPHONATES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MALE;

EID: 0035147163     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200101000-00013     Document Type: Article

References (18)

1. The French LCH Study Group. A multi-center retrospective survey of LCH: 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17.
2. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of LCH: 25 year experience at the University of California, San Francisco. J Clin Oncol 1996; 14:2073.
3. Munn SE, Olliver L, Broadbent V, et al. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999; 4:247-9.
4. Elomaa I, Blomqvist C, Porkka L, et al. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med 1989; 1:59-61.
5. Pivonello R, Faggiano A, Di Somma C, et. al. Effect of short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. J Clin Endocrin Metab 1999; 84:2349-52.
6. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment. Blood 1999; 94:1-8.
7. Brown RE. Angiotensin converting enzyme, transforming growth factor-beta and interleukin-11 in the osteolytic lesions of Langerhans cell histiocytosis. Arch Pathol Lab Med in press.
8. Arenzana-Seisdedos F, Barbey S, Virelizier JL, et al. Histiocytosis X purified [T6+] cells from bone granuloma produce interleukin l and prostaglandin E2 in culture. J Clin Invest 1986; 77:326-9.
9. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997; 69:1-18.
10. Abildgaard N, Rungby J, Glerup H, et al. Long term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998; 61:128-34.
11. Niskikawa M, Akatsu T, Katayama Y, et al. Biphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18:9-14.
12. Selander KS, Monkkonen J, Karhukorpi E, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1995; 50:1127-38.
13. D’Souza MJ, Oettinger CW, Shah A, et al. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage-dependent glomerulonephritis. Drug Dev Ind Pharm 1999; 25:591-6.
14. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: Geranylgeraniol, and intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 6:133-8.
15. Caux C, Deautter-Dambuyant C, Schmitt D, et al. GM-CSF and TNFa cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360:258.
16. Liens D, Delmas PD, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343:953-4.
17. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76:266-83.
18. Shoemaker L. Expanding role of biphosphonate therapy in children. J Pediatr 1999; 134:264-7.